0001161697-21-000521.txt : 20211110 0001161697-21-000521.hdr.sgml : 20211110 20211110161619 ACCESSION NUMBER: 0001161697-21-000521 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPRO MED SYSTEMS INC CENTRAL INDEX KEY: 0000704440 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133044880 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39086 FILM NUMBER: 211396841 BUSINESS ADDRESS: STREET 1: 24 CARPENTER RD CITY: CHESTER STATE: NY ZIP: 10918 BUSINESS PHONE: 845-469-2042 MAIL ADDRESS: STREET 1: 24 CARPENTER RD CITY: CHESTER STATE: NY ZIP: 10918 8-K 1 form_8-k.htm FORM 8-K CURRENT REPORT FOR 11-10-2021
0000704440 false 0000704440 2021-11-10 2021-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)   November 10, 2021

 

REPRO MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

 

New York 0-12305 13-3044880
(State or other jurisdiction
of incorporation)		 (Commission
File Number)		 (IRS Employer
Identification No.)

 

24 Carpenter Road, Chester, New York 10918
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code   (845) 469-2042

 

not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[_]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
common stock, $0.01 par value KRMD The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  [_]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

 

 

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On November 10, 2021, Repro Med Systems, Inc. dba KORU Medical Systems (“KORU Medical”) issued a press release announcing its financial results for the third quarter ended September 30, 2021. A related conference call will be held on November 10, 2021 at 4:30 pm Eastern Time.

 

KORU Medical is making reference to non-GAAP financial measures in both the press release and the conference call. Our management believes that investors’ understanding of KORU Medical’s performance is enhanced by disclosing the non-GAAP financial measures of Adjusted EBITDA, Adjusted EPS and Adjusted Net Sales (each as defined below) as a reasonable basis for comparison of our ongoing results of operations. KORU Medical strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by KORU Medical may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of GAAP to non-GAAP results is provided in the attached Exhibit 99.1 press release.

 

We define Adjusted EBITDA as earnings (net (loss)/income) before interest expense/(income), net, income tax (benefit)/expense, depreciation and amortization, reorganization charges, discontinued product expense, litigation expenses, manufacturing initiative expenses and stock-based compensation expense. We believe that Adjusted EBITDA is used by investors and other users of our financial statements as a supplemental financial measure that, when viewed with our GAAP results and the accompanying reconciliation, we believe provides additional information that is useful to gain an understanding of the factors and trends affecting our business. We also believe the disclosure of Adjusted EBITDA helps investors meaningfully evaluate and compare our cash flow generating capacity from quarter to quarter and year to year. Adjusted EBITDA is used by management as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations. Because management uses Adjusted EBITDA for such purposes, KORU Medical uses Adjusted EBITDA as a significant criterion for determining the amount of annual cash incentive compensation paid to our executive officers and employees. We have historically found that Adjusted EBITDA is superior to other metrics for our company-wide cash incentive program, as it is more easily explained and understood by our typical employee.

 

We present diluted earnings per share after eliminating items that we believe are not part of our ordinary operations and affect the comparability of the periods presented (“Adjusted EPS”). Adjusted EPS includes adjustments for reorganization charges, discontinued product expense, litigation expenses, manufacturing initiative expenses, stock-based compensation expense, and tax (expense). We believe adjustments for these items allow investors to better understand our underlying operating results and facilitate comparisons between the periods shown. Management uses Adjusted EPS as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations.

 

We present net sales after adjusting for net sales that we believe would have been made during periods other than those in which they were made, due to the pandemic and an early order (“Adjusted Net Sales”). We believe adjustments for these items allow investors to better understand our underlying net sales results and facilitate comparisons between the periods shown. Management uses Adjusted Net Sales as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits.

 

Exhibit No. Description
   
99.1 Press release dated November 10, 2021
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

- 2 -

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REPRO MED SYSTEMS, INC.
(Registrant)
     
Date:  November 10, 2021 By: /s/ Karen Fisher
  Karen Fisher
Chief Financial Officer

 

- 3 -

 EX-99 2 ex_99-1.htm PRESS RELEASE DATED NOVEMBER 10, 2021

 

EXHIBIT 99.1

 

KORU MEDICAL SYSTEMS ANNOUNCES 2021 THIRD QUARTER FINANCIAL RESULTS

 

CHESTER, NY – November 10, 2021 – Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the third quarter ended September 30, 2021.

 

Recent Highlights:

 

● Achieved net revenue of $6.0 million, a 9% increase versus Q2 2021, marking the third consecutive quarter of positive sequential growth
   
● Received FDA 510(k) clearance for CSL Hizentra® 20 ml prefilled syringe with the Freedom Edge® Syringe Infusion System
   
● Appointed three leadership team hires and announced an external innovation collaboration
   
● Scheduled strategic plan update presentation on December 2, 2021

 

“Our strong third quarter top-line results reflect continued momentum in all areas of our business – core US and international, as well as our novel therapies pipeline,” said Linda Tharby, KORU Medical’s CEO. “I’m proud of the team’s progress this quarter as we strengthen our foundation, continue to build the KORU Medical team, and increase our investment in innovation. We remain focused on continued execution of our strategy, which drives incremental growth and market expansion building on our leadership position in large volume subcutaneous home infusion and extending that position into new drug therapies.”

 

Third Quarter 2021 Financial Results

 

Net revenue was $6.0 million, (0.7)% lower compared with $6.1 million in the prior-year period. Adjusting for net inventory stocking of $0.6 million last year, adjusted net revenue grew 9%, with growth in all areas of our business; domestic core driven by pumps, international driven by consumables and increased novel therapies revenues. Sequential quarterly net revenue growth was 9%, with domestic core growth of 10% driven by pumps and needle sets and growth in novel therapies revenue.

 

Gross margin was 57.9% for the third quarter of 2021, a decline from prior year of 64.8%. The majority of the decline was driven by delays in the transition to our secondary manufacturing source. We also recorded a reserve for in-process material scrap. This was partially offset by favorability in product mix. We are confident in our path to accelerate margin improvement in 2022.

 

 

Total operating expenses for the third quarter of 2021 were $4.8 million, compared to $3.6 million for the same period in 2020. The increase in operating expenses is due to increased spend in support of strategic initiatives including commercialization, regulatory filings, and research and development.

 

Net loss for the third quarter of 2021 was $1.1 million, or $(0.02) per diluted share, compared with net income of $0.2 million, or $0.01 per diluted share for the same period in 2020.

 

About KORU Medical Systems

 

KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

 

Forward-looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by words such as “scheduled”, “our path”, and “look forward”. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, COVID-19, innovation and competition, and those risks and uncertainties included under the captions “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, which is on file with the SEC and is available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of November 10, 2021. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

 

Investor Contact:

 

Greg Chodaczek

347-620-7010

investor@korumedical.com

 

- 2 -

 

REPRO MED SYSTEMS, INC.

BALANCE SHEETS

(UNAUDITED)

 

    September 30,   December 31,  
    2021   2020  
               
ASSETS              
               
CURRENT ASSETS              
Cash and cash equivalents   $ 26,233,411   $ 27,315,286  
Accounts receivable less allowance for doubtful accounts of $24,469 for September 30, 2021 and December 31, 2020     3,122,665     2,572,954  
Inventory     6,967,932     6,829,772  
Prepaid expenses     1,336,819     807,780  
TOTAL CURRENT ASSETS     37,660,827     37,525,792  
Property and equipment, net     1,159,819     1,167,623  
Intangible assets, net of accumulated amortization of $248,252 and $199,899 at September 30, 2021 and December 31, 2020, respectively     821,071     843,587  
Operating lease right-of-use assets     131,228     236,846  
Deferred income tax assets, net     1,565,334     125,274  
Other assets     19,812     19,812  
TOTAL ASSETS   $ 41,358,091   $ 39,918,934  
               
LIABILITIES AND STOCKHOLDERS’ EQUITY              
               
CURRENT LIABILITIES              
Accounts payable   $ 1,385,413   $ 624,920  
Accrued expenses     2,036,848     2,610,413  
Accrued payroll and related taxes     332,814     287,130  
Finance lease liability – current     414     2,646  
Operating lease liability – current     131,228     141,293  
Note Payable     673,133     —  
TOTAL CURRENT LIABILITIES     4,559,850     3,666,402  
Operating lease liability, net of current portion     —     95,553  
TOTAL LIABILITIES     4,559,850     3,761,955  
Commitments and contingencies (Refer to Note 3)              
STOCKHOLDERS’ EQUITY              
Common stock, $0.01 par value, 75,000,000 shares authorized, 47,931,664 and 46,680,119 shares issued 44,511,162 and 43,259,617 shares outstanding at September 30, 2021 and December 31, 2020, respectively     479,317     466,801  
Additional paid-in capital     40,004,197     35,880,986  
Treasury stock, 3,420,502 shares at September 30, 2021 and December 31, 2020, at cost     (3,843,562 )   (3,843,562 )
Retained earnings     158,289     3,652,754  
TOTAL STOCKHOLDERS’ EQUITY     36,798,241     36,156,979  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 41,358,091   $ 39,918,934  

 

- 3 -

 

REPRO MED SYSTEMS, INC.

STATEMENTS OF OPERATIONS

(Unaudited)

 

    Three Months Ended   Nine Months Ended  
    September 30,   September 30,  
    2021   2020   2021   2020  
                           
NET SALES   $ 6,040,544   $ 6,080,315   $ 16,999,669   $ 20,119,228  
Cost of goods sold     2,544,794     2,139,592     7,061,881     7,480,415  
Gross Profit     3,495,750     3,940,723     9,937,788     12,638,813  
                           
OPERATING EXPENSES                          
Selling, general and administrative     3,901,830     3,075,169     12,980,604     9,039,980  
Litigation     —     675     —     2,446,747  
Research and development     800,020     390,416     1,523,739     944,637  
Depreciation and amortization     115,934     115,637     349,822     297,801  
Total Operating Expenses     4,817,784     3,581,897     14,854,165     12,729,165  
                           
Net Operating (Loss)/Profit     (1,322,034 )   358,826     (4,916,377 )   (90,352 )
                           
Non-Operating (Expense)/Income                          
(Loss)/Gain on currency exchange     (7,283 )   1,927     (21,761 )   (11,164 )
Gain on disposal of fixed assets, net     273     22,113     1,009     16,591  
Interest (expense)/income, net     (2,838 )   9,662     16,883     23,690  
TOTAL OTHER (EXPENSE)/INCOME     (9,848 )   33,702     (3,869 )   29,117  
                           
(LOSS)/INCOME BEFORE INCOME TAXES     (1,331,882 )   392,528     (4,920,246 )   (61,235 )
                           
Income Tax Benefit/(Expense)     238,104     (143,353 )   1,425,781     (316,200 )
                           
NET (LOSS)/INCOME   $ (1,093,778 ) $ 249,175   $ (3,494,465 ) $ (377,435 )
                           
NET (LOSS)/INCOME PER SHARE                          
                           
Basic   $ (0.02 ) $ 0.01   $ (0.08 ) $ (0.01 )
Diluted   $ (0.02 ) $ 0.01   $ (0.08 ) $ (0.01 )
                           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                          
                           
Basic     44,322,335     43,914,542     44,510,021     41,326,815  
Diluted     44,322,335     44,119,511     44,510,021     41,326,815  

 

- 4 -

 

REPRO MED SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

    For the
Nine Months Ended		  
    September 30,  
    2021   2020  
               
CASH FLOWS FROM OPERATING ACTIVITIES              
Net Loss   $ (3,494,465 ) $ (377,435 )
Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:              
Stock-based compensation expense     1,967,632     1,191,146  
Stock-based litigation settlement expense     —     1,285,102  
Depreciation and amortization     349,822     297,801  
Deferred income taxes     (1,440,060 )   (161,368 )
Gain on disposal of fixed assets     (1,009 )   (16,591 )
               
Changes in operating assets and liabilities:              
Increase in accounts receivable     (549,711 )   (502,075 )
Increase in inventory     (138,160 )   (3,244,662 )
Increase in prepaid expenses and other assets     (529,039 )   (457,330 )
Increase in accounts payable     760,493     790,414  
Increase in accrued payroll and related taxes     45,684     249,879  
(Decrease)/Increase in accrued expenses     (573,565 )   1,754,970  
Increase in accrued tax liability     —     158,586  
NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES     (3,602,378 )   968,437  
               
CASH FLOWS FROM INVESTING ACTIVITIES              
Purchases of property and equipment     (301,720 )   (908,323 )
Proceeds from disposal of property and equipment     9,065     25,000  
Purchases of intangible assets     (25,838 )   (124,216 )
NET CASH USED IN INVESTING ACTIVITIES     (318,493 )   (1,007,539 )
               
CASH FLOWS FROM FINANCING ACTIVITIES              
Borrowings from indebtedness     924,389     4,976,508  
Payments on indebtedness     (251,255 )   (4,976,508 )
Proceeds from issuance of equity     1,230,000     26,606,486  
Common stock issuance as settlement for litigation     938,094     —  
Payments on finance lease liability     (2,232 )   (4,502 )
NET CASH PROVIDED BY FINANCING ACTIVITIES     2,838,996     26,601,984  
               
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS     (1,081,875 )   26,562,882  
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD     27,315,286     5,870,929  
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 26,233,411   $ 32,433,811  
               
Supplemental Information              
Cash paid during the periods for:              
Interest   $ 6,194   $ 27,698  
Income Taxes   $ 850   $ 318,983  
               
Schedule of Non-Cash Operating, Investing and Financing Activities:              
Issuance of common stock as compensation   $ 295,947   $ 180,006  
Issuance of common stock as settlement for litigation   $ 938,094   $ 938,094  

 

- 5 -

 

REPRO MED SYSTEMS, INC.

SUPPLEMENTAL INFORMATION

(UNAUDITED)

 

The following table summarizes our net sales for the three and nine months ended September 30, 2021 and 2020:

 

  Three Months
Ended September 30,		   Nine Months
Ended September 30,
  2021   2020   2021   2020
Net Sales                    
Domestic $ 5,076,294   $ 5,289,076   $ 14,084,552   $ 15,719,419
International   747,281     702,034     2,585,881     2,539,944
Novel Therapies   216,969     89,205     329,236     1,859,865
Total $ 6,040,544   $ 6,080,315   $ 16,999,669   $ 20,119,228

 

 

A reconciliation of one of our non-GAAP measures is below:

 

Reconciliation of Reported Net Sales to Non-GAAP Net Sales   Three Months
Ended September 30,		   Change from Prior Year  
    2021   2020   $   %  
Reported Net Sales   $ 6,040,544   $ 6,080,315   $ (39,771 ) (0.7% )
Early Order/Inventory Stocking     —     (552,000 )   552,000   (100.0% )
Non-GAAP Adjusted Net Sales   $ 6.040,544   $ 5,528,315   $ 512,229   9.3%  

 

 

Reconciliation of Reported Net Sales to Non-GAAP Net Sales   Nine Months
Ended September 30,		   Change from Prior Year  
    2021   2020   $   %  
Reported Net Sales   $ 16,999,669   $ 20,119,228   $ (3,119,559 ) (15.5% )
Early Order/Inventory Stocking     —     (1,335,000 )   1,335,000   (100.0% )
Non-GAAP Adjusted Net Sales   $ 16,999,669   $ 18,784,228   $ (1,784,559 ) (9.5% )

 

Early Order/Inventory Stocking.  We have excluded the effect of an early order and covid related inventory stocking in calculating our non-GAAP measure.  We had an early order from our largest distributor in the three months ended September 30, 2020, which would have otherwise been placed in the three months ended December 31, 2020, as well as higher purchases in the six months ended June 30, 2020, that we believe would have normally been made in the second half of 2020, had it not been for the pandemic.

 

- 6 -

 

REPRO MED SYSTEMS, INC.

SUPPLEMENTAL INFORMATION

(UNAUDITED)

 

A reconciliation of our non-GAAP measures is below:

 

    Three Months Ended   Nine Months Ended
Reconciliation of GAAP Net (Loss)/Income   September 30,   September 30,
to Non-GAAP Adjusted EBITDA:   2021     2020   2021   2020
GAAP Net Loss   $ (1,093,778 )   $ 249,175   $ (3,494,465 ) $ (377,435 )
Tax (Benefit)/Expense     (238,104 )     143,353     (1,425,781 )   316,200  
Depreciation and Amortization     115,934       115,637     349,822     297,801  
Interest Expense/(Income), Net     2,838       (9,662 )   (16,883 )   (23,690 )
Reorganization Charges     (1,262 )     —     1,192,618     —  
Discontinued Product Expenses     —       (6,659 )   —     71,318  
Litigation Expenses     —       675     —     2,446,747  
Manufacturing Initiative Expenses     35,892       59,045     237,333     194,804  
Stock-based Compensation Expense     628,276       406,325     1,967,632     1,191,146  
Non-GAAP Adjusted EBITDA   $ (550,204 )   $ 957,889   $ (1,189,724 ) $ 4,116,891  

 

 

    Three Months Ended   Nine Months Ended
Reconciliation of Reported Diluted EPS   September 30,   September 30,
to Non-GAAP Adjusted Diluted EPS*:   2021     2020   2021   2020
Reported Diluted Earnings Per Share   $ (0.02 )   $ 0.01   $ (0.08 ) $ (0.01 )
Reorganization Charges     —       —     0.03     —  
Discontinued Product Expense     —       —     —     —  
Litigation Expenses     —       —     —     0.06  
Manufacturing Initiative Expenses     —       —     0.01     —  
Stock-based Compensation Expense     —       —     0.01     —  
Tax (Expense) Adjustment     —       —     (0.01 )   (0.01 )
Non-GAAP Adjusted Diluted Earnings Per Share   $ (0.02 )   $ 0.01   $ (0.04 ) $ 0.04  

 

*Numbers presented are rounded to the nearest whole cent

 

Reorganization Charges.  We have excluded the effect of reorganization charges in calculating our non-GAAP measures.  We incurred significant expenses in connection with the departure and replacement of our chief executive officer and the recruiting of two new board members, which we would not have otherwise incurred in periods presented as part of our continuing operations.

 

Discontinued Product Expense.  We have excluded the effect of expenses related to a discontinued product line in calculating our non-GAAP measures.  We did not incur any related expense in 2021.

 

Litigation.  We have excluded litigation expenses in calculating our non-GAAP measures.  Litigation expenses in 2020 included professional fees associated with our litigation with EMED, which discontinued as a result of the settlement on May 20, 2020.

 

Manufacturing Initiative Expenses.  We have excluded the effect of expenses related to creating manufacturing efficiencies, in calculating our non-GAAP measures.  We incurred expenses in connection with these initiatives which we would not have otherwise incurred in periods presented as part of our continuing operations.  We expect to incur related expenses for the next six to nine months.

 

Stock-based Compensation Expense.  We have excluded the effect of stock-based compensation expense in calculating our non-GAAP measures.  We record non-cash compensation expense related to grants of options for executives, employees and consultants, and grants of common stock to our board of directors and our CEO.  Depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods. Adjusted EBITDA for the nine months ended September 30, 2021 included stock-based compensation expense of $0.4 million related to the departure and replacement of our chief executive officer. This expense is the only amount included in Stock-based Compensation Expense in calculating Adjusted Diluted EPS.

 

- 7 -

 EX-101.SCH 3 krmd-20211110.xsd INLINE XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 krmd-20211110_lab.xml INLINE XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 krmd-20211110_pre.xml INLINE XBRL PRESENTATION FILE GRAPHIC 6 koru_logo.jpg GRAPHIC begin 644 koru_logo.jpg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end XML 7 form_8-k_htm.xml IDEA: XBRL DOCUMENT 0000704440 2021-11-10 2021-11-10 iso4217:USD shares iso4217:USD shares 0000704440 false 8-K 2021-11-10 REPRO MED SYSTEMS, INC. NY 0-12305 13-3044880 24 Carpenter Road Chester NY 10918 845 469-2042 false false false false common stock, $0.01 par value KRMD NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 10, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 10, 2021
Entity File Number 0-12305
Entity Registrant Name REPRO MED SYSTEMS, INC.
Entity Central Index Key 0000704440
Entity Tax Identification Number 13-3044880
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 24 Carpenter Road
Entity Address, City or Town Chester
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10918
City Area Code 845
Local Phone Number 469-2042
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security common stock, $0.01 par value
Trading Symbol KRMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://repro-med.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form_8-k.htm ex_99-1.htm krmd-20211110.xsd krmd-20211110_lab.xml krmd-20211110_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form_8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form_8-k.htm" ] }, "labelLink": { "local": [ "krmd-20211110_lab.xml" ] }, "presentationLink": { "local": [ "krmd-20211110_pre.xml" ] }, "schema": { "local": [ "krmd-20211110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "krmd", "nsuri": "http://repro-med.com/20211110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "div", "body", "html" ], "baseRef": "form_8-k.htm", "contextRef": "From2021-11-10to2021-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://repro-med.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "div", "body", "html" ], "baseRef": "form_8-k.htm", "contextRef": "From2021-11-10to2021-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://repro-med.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001161697-21-000521-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001161697-21-000521-xbrl.zip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end